Skip to content

    Dhanuka Agritech

    DHANUKA
    Chemicals·16 May 2025
    Management Summary

    Dhanuka Agritech delivered strong financial results for Q4 and FY25, achieving record revenue and significant margin expansion. The company made a strategic move into global markets with the acquisition of international rights for two fungicide molecules. While the Dahej plant remains a drag on profitability, management is optimistic about future growth driven by new product launches and a favorable monsoon, despite anticipated gross margin pressures from raw material costs.

    Highlights

    5

    • Revenue from operations for FY25 grew by 15.73% to ₹2035.15 crores, surpassing the ₹2000 crore milestone.

    • EBITDA for FY25 increased by 27.23% to ₹416.61 crores, with EBITDA margin improving by 180 bps to 20.47%.

    • Profit after tax for FY25 rose by 24.2% to ₹296.96 crores, with PAT margin improving by 99 bps to 14.59%.

    • Acquired international rights for two fungicide molecules from Bayer AG, marking a strategic entry into global markets with expected revenue contribution of ₹110 crores in FY26.

    • Board recommended a 100% dividend of ₹2 per equity share, demonstrating commitment to shareholder returns.

    Concerns

    3

    • The Dahej plant continues to operate at a negative EBITDA of ₹14 crores in FY25, with profitability requiring 70-80% capacity utilization (currently at 25%, projected 35% for FY26).

    • Gross margin is expected to be impacted by a 100 basis point hit in FY26 due to stabilizing/increasing raw material prices.

    • Trade receivables have gone up significantly in Q4 FY25, though management expects them to come down sharply in Q1 FY26.

    What Changed2

    vs Q1 FY26

    Guidance items7 → 13 (+6)Risks discussed4 → 3 (-1)
    Key financials

    Metrics

    12

    Periods

    2

    Q4 FY25

    6
    • Revenue
      ₹442.02 Cr
      YoY+20.0%
    • EBITDA
      ₹1,095.75 Cr
      YoY+37.0%
    • EBITDA Margin
      24.8%
    • PAT
      ₹75.5 Cr
      YoY+27.9%
    • PAT Margin
      17.1%

    FY25

    6
    • Revenue
      ₹2,035.15 Cr
      YoY+15.7%
    • EBITDA
      ₹416.61 Cr
      YoY+27.2%
    • EBITDA Margin
      20.5%
    • PAT
      ₹296.96 Cr
      YoY+24.2%
    • PAT Margin
      14.6%

    Segment breakdown

    Zone-wise Turnover (Q4 FY25)
    34% North Zone12% East Zone20% West Zone34% South Zone
    Product Category-wise Turnover (Q4 FY25)
    38% Insecticides13% Fungicides32% Herbicides17% Others
    Sales Channel (FY25)
    9% B2B Sales91% Brand Sales
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Dividend

    ₹2/share (final)

    M&A

    International rights for two fungicide molecules (iprovalicarb and triadimenol) from Bayer AG

    acquisition · closed

    Liquidity

    Liquidity disclosed

    Cash position is quite healthy and expected to keep building up.

    Guidance & targets

    13
    CategoryTargetPriority
    Revenue
    Revenue Growth
    higher double digit growth
    		High
    Revenue
    Dahej Plant Revenue
    ₹60 crores
    		High
    Revenue
    Bayer Products Revenue
    ₹110 crores
    		High
    Revenue
    Bayer Products Royalty/Economic Benefit
    ₹15-20 crores
    		High
    Revenue
    Overall Exports (excluding Bayer)
    ₹60 crores
    		High
    Profitability
    EBITDA Margin
    remain on similar lines as this year
    		High
    Profitability
    Dahej Plant EBITDA
    similar lines (negative)
    		High
    Profitability
    Gross Margin Impact
    100 basis point hit
    		High
    Profitability
    EBITA Margin
    maintaining this year percentage
    		High
    Capacity
    Dahej Capacity Utilization
    35%
    		High
    Capacity
    Dahej Capacity Utilization for Positive EBITDA
    70% to 80%
    		High
    New Product Launch
    Paddy Herbicide Launch
    this month
    		High
    New Product Launch
    Japanese Fungicide Launch
    next quarter
    		High

    Dahej Plant Revenue & EBITDA

    Next quarter (Q1 FY26) and FY26
    Current₹40 crores revenue, ₹-14 crores EBITDA (FY25)
    Target₹60 crores revenue, EBITDA 'in similar lines' (negative) (FY26)

    Why it matters

    Tracking the progress of the Dahej plant towards profitability and its contribution to overall revenue.

    So Dahej performance last year was revenue of Rs.40 crores in FY'25 and for the coming year we are looking at a revenue of Rs.60 crores from Dahej and in terms of EBITDA last year was negative EBITDA of Rs.14 crores, and this year the EBITDA will be in the similar lines.

    How to verify

    guidance_and_targets

    Risks & concerns

    3
    RiskSeverity

    Raw Material Price Volatility

    Management expects a 100 bps hit to gross margin in FY26 as raw material prices stabilize/increase after a period of decline. — Management acknowledged

    medium

    Dahej Plant Profitability

    The Dahej plant is currently operating at a negative EBITDA (₹14 crores in FY25) and needs 70-80% utilization to break even, currently at 25% (expected 35% in FY26). — Management acknowledged

    medium

    International Market Performance

    Analyst noted the international agri market is not doing well for other players, but management sees opportunity for Dhanuka with its new acquisitions and global expansion strategy. — Analyst downplayed

    low

    Q&A highlights

    8

    “So Dahej performance last year was revenue of Rs.40 crores in FY'25 and for the coming year we are looking at a revenue of Rs.60 crores from Dahej and in terms of EBITDA last year was negative EBITDA of Rs.14 crores, and this year the EBITDA will be in the similar lines. Sorry, with respect to your first question on the monsoon forecast being good, so both IMD and SKYNET have given a positive monsoon forecast at 105% of LPA, which means that the initial sentiment is quite positive for the growers to plant their fields. On the revenue this year, what we are planning is a higher double digit growth and on the EBITDA, we expected to remain on similar lines as this year.”

    Analyst sought forward guidance based on favorable monsoon and the company's new base. Management provided specific revenue and EBITDA targets for Dahej and overall, along with monsoon outlook.

    asked by Rohit Nagraj

    2 min read6 chapters

    Detailed Narrative

    01

    Robust Financial Performance in FY25

    Dhanuka Agritech achieved a milestone revenue of ₹2035.15 crores in FY25, marking a 15.73% increase year-on-year. EBITDA for the full year grew by 27.23% to ₹416.61 crores, with the EBITDA margin expanding by 180 basis points to 20.47%. Profit after tax also saw robust growth of 24.2% to ₹296.96 crores, resulting in a PAT margin improvement of 99 basis points to 14.59%. For Q4 FY25, revenue from operations was ₹442.02 crores, up 20.01% YoY, and EBITDA was ₹1095.75 crores, up 37.03% YoY, with a margin of 24.83%.

    02

    Strategic Global Expansion with Bayer Acquisition

    The company acquired international rights for two key fungicide molecules, iprovalicarb and triadimenol, from Bayer AG, Germany. This strategic move provides Dhanuka Agritech with a presence in over 20 countries across Latin America, Europe, Asia, and Africa. The total addressable market for these molecules is estimated at ~$100 million US. These products are projected to contribute approximately ₹110 crores in revenue and ₹15-20 crores in royalty/economic benefit in FY26, building on the ₹12 crores received in Q4 FY25.

    03

    Dahej Plant Performance and Path to Profitability

    The Dahej manufacturing unit generated ₹40 crores in revenue in FY25 but incurred a negative EBITDA of ₹14 crores. For FY26, revenue is projected to increase to ₹60 crores, though EBITDA is expected to remain negative. Management indicated that the plant's capacity utilization, currently at 25% (expected to rise to 35% in FY26), needs to reach 70-80% to achieve positive EBITDA, highlighting the ongoing efforts to scale operations.

    04

    Product Portfolio and Market Strategy

    Dhanuka Agritech's Q4 FY25 product mix was 38% insecticides, 32% herbicides, 13% fungicides, and 17% others. B2B sales constituted about 9% of total revenue in FY25, a significant increase from 4% last year, driven by a strategic focus on building channels for future products from Dahej. The company plans to introduce new products, including a paddy herbicide this month and a Japanese fungicide next quarter, to continuously upgrade its portfolio and drive growth.

    05

    Monsoon Outlook and Raw Material Headwinds

    The company anticipates a positive monsoon forecast (105% of LPA) for the upcoming Kharif season, which is expected to support higher double-digit revenue growth in FY26. However, management foresees a 100 basis point hit to gross margins in FY26 due to the stabilization and potential increase in raw material prices, following a period of continuous decline. This indicates a focus on cost pass-through and product mix to mitigate margin pressure.

    06

    Shareholder Returns and Liquidity Management

    The Board recommended a 100% dividend of ₹2 per equity share for FY25, absorbing ₹9.02 crores. This follows a buyback of 5 lakh shares at ₹2000 per share conducted in Q2 FY25. Management affirmed a 'healthy' cash position, which is expected to continue building up, supporting future growth initiatives and consistent shareholder returns without specific numerical disclosures on cash balances.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.